Nicholas Investment Partners LP Makes New $2.86 Million Investment in Silence Therapeutics plc (NASDAQ:SLN)

Nicholas Investment Partners LP purchased a new position in Silence Therapeutics plc (NASDAQ:SLN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 150,480 shares of the company’s stock, valued at approximately $2,859,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after buying an additional 667 shares during the period. Custom Index Systems LLC acquired a new position in Silence Therapeutics during the second quarter valued at $282,000. Legato Capital Management LLC acquired a new position in Silence Therapeutics during the second quarter valued at $376,000. Parkman Healthcare Partners LLC lifted its position in Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Finally, Lynx1 Capital Management LP increased its holdings in Silence Therapeutics by 123.4% in the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after buying an additional 290,855 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Stock Down 1.3 %

SLN stock opened at $18.56 on Thursday. Silence Therapeutics plc has a 52 week low of $6.15 and a 52 week high of $27.72. The stock has a market capitalization of $555.50 million, a P/E ratio of -16.00 and a beta of 1.29. The firm has a 50-day simple moving average of $18.73 and a 200-day simple moving average of $20.78.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.10). The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $11.28 million. Silence Therapeutics had a negative net margin of 222.44% and a negative return on equity of 58.28%. On average, analysts expect that Silence Therapeutics plc will post -1.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, August 30th. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective for the company. Morgan Stanley lifted their price objective on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a report on Friday, June 28th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Friday, August 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Silence Therapeutics presently has a consensus rating of “Buy” and an average price target of $57.20.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.